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Background: To describe the prevalence, patterns of blood use, and outcomes of major haemorrhage in trauma. 
Methods: Prospective observational study at 22 hospitals in UK, including major trauma centres and trauma units. Eligible patients were those receiving at least four units of red cells in the first 24 hours of admission with activation of the massive haemorrhage protocol. Local case notes, transfusion charts and blood bank records were accessed; and copies of prescription/theatre charts were reviewed centrally. Outcomes were use of blood components, mortality at 30 days and one year; and critical care hospital stay. 
Results: Median enrolment period was 20 months (range 7-24) for all centres. 74% of 442 patients were male with average age 38 years; the incidence increased markedly over 60 years. The national incidence was estimated as 83 in 1,000,000. Almost half of deaths within 24 hours of admission occurred within the first 3 hours. At 24 hours 7974 patients (1817%) had died,, but mortality continued to rise after discharge., and at one year nearly half of all haemorrhage patients requiring 10 units of red cells had died.  Patients who received a cumulative ratio of FFP to red cells >=1:2, showed lower rates of death, compared to those receiving ratios of <1:2. There were delays in administration of blood, and platelets and cryoprecipitate either not given or if transfused, at time periods well after initial resuscitation. 




Trauma haemorrhage makes a considerable contribution to the global burden of disease yet its natural history and outcomes at a population level remain unclear and under-appreciated.  Bleeding following injury is estimated to be responsible for over 2 million deaths annually and even in specialist centres massive haemorrhage may carry a hospital mortality of over 50%.1,2,3,4 However the overall incidence, natural history and outcomes of trauma haemorrhage are not well described across a health system.  New management strategies have been introduced which include the rapid and consistent administration of transfusion therapy to correct coagulopathy. 5,6  While seemingly effective in the context of academic trauma centres 7 it is not clear how effectively these strategies have been implemented or how successful they are across the board. 8  There may be important opportunities for improvement if real-world management patterns can be described and mapped against current best practice.

In recent years there has been increasing interest in trauma haemorrhage, as civilian and military studies have focused on this high burden of potentially preventable deaths.  The discovery of the endogenous acute traumatic coagulopathy has led to a new management paradigm of damage control resuscitation.9  This strategy focuses on the early delivery of red cells and high doses of plasma fractions 10,11,12,13,14,15,16  to maintain hemostatic potential by treating the early coagulopathy and preventing further dilution of factors.  In some reports these strategies have appeared to halve mortality in the most severely bleeding patients.  However the rapid and consistent delivery of blood, plasma, platelets and other products can be extremely challenging in the emergency environment and delays and gaps in product availability can occur.  In particular the early availability of blood components and the ability to deliver them consistently in high dose alongside red cells appears to be important in maintaining hemostatic competence.  While there has been broad acceptance of the concepts within damage control resuscitation, challenges with implementation may reduce its effectiveness, while offering areas to focus improvements in clinical pathways. 





This prospective multi-centre cross-sectional observational study was conducted in collaboration with the Trauma Audit and Research Network (TARN), an independent monitor of trauma care in England and Wales. Hospitals that participate in TARN collect data on all TARN eligible trauma admissions, including characteristics of the injury, details of interventions, for example, surgical or radiological investigations, and patient outcomes, including deaths in hospital and survival status (dead or alive) at 30 days post discharge.

Participating Centres
The selection of participating trauma departments was based on geographical distribution across England and size of hospital or emergency department - to ensure an approximate equal regional distribution between large, multi-specialty trauma centres and medium hospitals with trauma units.  The selection of participating hospitals was also based on local support and interest from senior medical staff and centres with a record of consistent participation in TARN defined by measures of audit quality control. 

Patients
The study cohort comprised data collected on adult trauma patients aged 16 years and over admitted to one of the 22 participating trauma EDs.  Eligible patients fulfilled the TARN inclusion criteria (injuries that result in a hospital stay of 72 hours or more, transfer for specialist or intensive care or patient death) and received at least four units of red cells in the first 24 hours of admission with activation of the massive haemorrhage protocol (MHP). 17,18 The rationale for requiring MHP activation was to identify the more severely injured bleeding trauma patients, in contrast to those patients who would receive at least four units of red cells in the first 24 hours of admission for complications such as semi-urgent surgery. An organisational questionnaire asked about details of MHP at all centres, including criteria for activation. We also excluded patients transferred from another hospital.  For the purposes of this study, patients who received 4 or more units of red cells in the first 24 h were classed as having ‘major haemorrhage’. Those patients receiving 10 or more units of red cells in 24 h were classified as having ‘massive haemorrhage’, to identify the most severely injured subgroup of victims. 

Patient level outcome measures and data collection
Outcome measures were: 24-hour, 30 day and one year mortality, critical care in hospital stay, ventilator-free days and total length of stay, and transfusion requirements including use of red cells, plasma, platelets, cryoprecipitate. Severe injury was defined as injury severity score (ISS; 2008 version) >15. Following local approval, the TARN data coordinator allocated a unique anonymised identifying number aside from the patient’s hospital number. Additional data fields were created on the existing encrypted and password protected electronic web-based tool at TARN to collect information on use of blood components and timings of transfusions. Educational sessions and materials were provided to TARN co-ordinators at the participating hospitals. Local source data included patient case notes, transfusion prescription charts, and blood bank records. In addition, anonymised copies of all the prescription charts and theatre charts for the first 24 hours after admission were requested for central review, both to provide data and as a quality control check, which was undertaken in duplicate by two members of the research team.

Regulatory approvals
The National Research Ethics Committee (NREC) South Central Oxford B gave full ethical approval.  TARN already had Patient Information Advisory Group (PIAG) approval for data collection conduct research on anonymised data without consent.  A separate application to the National Information Governance Board Ethics and Confidentiality Committee (NIGB EEC) and NHS Medical Register Information Centre (MRIC) allowed the processing of patient identifiable information without consent and the collection of 1 year survival/mortality data for participants.  

Analysis plan
Continuous data were summarised using means and standard deviations or medians and inter-quartile ranges if not normally distributed.  Categorical data were summarised as frequencies and percentages.  For hourly intervals during the first 24 hours after admission the number of units of red blood cells, fresh frozen plasma, cryoprecipitate and platelets administered to patients was counted and the mean across all patients calculated.  The mean values were used as on an hourly basis as many patients did not receive FFP or PRBC (and so the medians were often zero). The median and inter-quartile range of the ratio of the cumulative number of units of FFP to cumulative number of units of PRBC was also calculated for each hour.  Medians were used as the distributions of the ratios across all patients each hour were skewed.  Logistic regression was used to assess the association between PRBC requirement and mortality. 

Dates of death and up to three causes of death were collected for those patients who died within a year of their injury.  TARN also provided data for all patients, who, during the study period, satisfied the TARN inclusion criteria and received at least one unit of red cells or blood components.  Baseline characteristics (gender, age, injury profile) for those patients in the trauma study (i.e. 4 units red cells or more) and those not (1-3 units red cells or blood components) were compared to gauge how representative the study population was of the wider transfused TARN population. All analysis has been performed using the statistical software SAS Version 9.1.3 (SAS Institute Inc., Cary, NC, USA).

Extrapolating from the trauma data to national figures
All cases of trauma in England are reported to Hospital Episode Statistics (HES).  Not all cases are reported to TARN but TARN does obtain estimates from HES of the extent of the under-reporting.  Estimates of the under-reporting from the 22 study centres throughout 2011 were obtained, categorised by age band (16-24, 25-34, 35-44, 45-54, 55-64, 65+) and gender. The under-reporting to TARN averaged 26%, but varied across the centres and age band / gender groups with some centres having complete reporting and a few centres having no reports of trauma within an age band / gender group.





Subjects were enrolled in the 24-month period between April 2009 and April 2011 and followed for one year.  Not all centres began recruitment at the same time depending on local ethics, resources and research staff.  The median time study open for enrolment at centres was 20 months, range 7-24). In total, 5210 TARN eligible patients were admitted across the 22 centres.  Of these, 484 study eligible cases were identified at the 22 recruiting hospitals. The recruiting centres included 12 major trauma centres (enrolling 349 patients) and 10 smaller trauma unitsother hospitals (enrolling 93 patients). 442 cases were retrospectively excluded as the patients were found to have received fewer than 4 units of red blood cells in the first 24 hours from admission, leaving a final dataset of 442 cases (Table 1). Of these, full details of timing and volume of blood components was available for 401 patients (91%). 

Incidence and Outcomes
Overall, 8% of the 5210 trauma patients at the institutions had major haemorrhage and 3% suffered massive haemorrhage.  For severely injured patients (ISS >15) 14% had major haemorrhage and 5% massive haemorrhage.   Of the 442 study patients meeting major haemorrhage criteria for this study, 81% were severely injured and 36% had massive haemorrhage.  

Nationally this extrapolated to an overall incidence of 83 per million for major haemorrhage and 23 per million for massive haemorrhage.  Of note, we identified a greatly increased likelihood of major haemorrhage in older trauma patients. The likelihood of suffering injury with haemorrhage was consistent across all age groups until the age of 65, at which point incidence almost doubled to 196 per million older patients for major haemorrhage and 50 per million for massive haemorrhage (Figure 1A).

Overall the outcomes from trauma haemorrhage were poor (Table 2).  One in four patients with major haemorrhage died in-hospital rising to over 1 in 3 for massive haemorrhage patients.  Seventy ninefour patients died within the first 24-hours – representing 6763% of all the in-hospital deaths (Figure 1B).  More than half of deaths in the first day occurred within the first 4 hours of arrival.  Mortality continued to rise after discharge, and 10 further cases of major haemorrhage had died at one year. , such thatOverall after one year nearly half of all massive haemorrhage patients had died.  Extrapolating these data to the annual national estimate of 4926 major haemorrhage trauma patients, 4128 patients would be admitted to critical care and 1635 (33%) would die (1325 by 30 days - 27%).

Transfusion management
Table 2 and figures 2A-D show information on patterns of transfusion use. The median 24-hour blood requirement was 7 units of PRBCs for the major haemorrhage group and 15 units for the massive haemorrhage group (Table 2).  The majority of PRBCs were transfused within the first 4 hours - 36% in the first hour and 55% in the first two hours (Figure 2A).  There was a strong relationship between the number of PRBCs required in the first 24 hours and mortality at 24 hours (likelihood ratio test p=0.002) and 30-days (p<0.001).  For every additional unit of PRBC required the odds of death at 24 hours increased by 5%, and by 9% per PRBC unit for 30 day mortality.  

The first unit of PRBCs was received at a median of 41 minutes after admission.  For those who received plasma, the median time to first FFP transfusion was 87 minutes from arrival, slightly faster for massive haemorrhage patients at 68 minutes.  The delivery of FFP fluctuated over time for individual patients and across the whole cohort, suggesting periods where component therapy was not available during active haemorrhage (Figure 2B).  In the first hour after admission, 16% of patients who survived the first 24 hours reached a FFP:RBC ratio of >1:2, 41% reached the ratio within 4 hours, and 55% within 24 hours (Figure 2C).  No FFP was transfused at all during resuscitation in 25% of major haemorrhage and 8% of massive haemorrhage patients.  Of the 7479 patients who died within 24 hours of admission, blood component information was unavailable for 5 patients, l. Leaving 74 cases with complete component data, .  Of these 74, 20 (27%) died without receiving FFP and 41 (55%) never reached a FFP:PRBC ratio ≥1:2. 

Table 3 shows the results for the ratios of cumulative FFP to cumulative RBC, for all patients who received at least one unit of plasma.  Patients who died within 1 hour were excluded for this analysis, as these patients in the very early mortality group would include those who died before any plasma could be administered, had massive exsanguination and/or might be considered futile. Higher ratios of FFP:PRBC were associated with lower mortality rates, with no apparent difference in injury severity or physiology between the groups.  Survival for patients who did not receive a balanced transfusion of FFP with PRBCs (<1:2) had a 3.6 times higher mortality after 3 hours, and 2.3 times higher mortality at 24 hours.

There were much longer delays in the delivery of platelet and cryoprecipitate transfusions (Figure 2D).  Time to first transfusion of platelets for major haemorrhage patients was a median of 2.3 hours after arrival and almost 3 hours for cryoprecipitate.  For massive haemorrhage initial delivery was slightly faster at 2.0 hours for platelets and 2.2 hours for cryoprecipitate. 19% of massive haemorrhage patients did not receive platelets and 48% did not receive any cryoprecipitate in the first 24 hours. 37 of the 74 patients who died within 24 hours of admission did not receive either platelets or cryoprecipitate. 
Discussion
Nearly five thousand patients have major trauma haemorrhage in England & Wales each year, and a third of these will die.  Critical haemorrhage affects all age groups and is a major public health issue for many countries. This study has identified several areas of specific focus for outcomes improvement, and important opportunities exist in the very early phases of care to improve current practice and to focus innovation in haemorrhage management.

Deaths from bleeding tend to occur early, with half of all deaths occurring in the first 24 hours, and half of these within three hours of admission.  Despite advances in trauma resuscitation and surgery, management is often too slow to cope with the rapidly exsanguinating patient.  Early control of bleeding is key, and our work supports a focus on innovation in methods to temporarily control haemorrhage.  Tourniquets have been reintroduced into clinical practice for extremity bleeding 20, and there is new interest in methods of temporary control of torso haemorrhage such as balloon occlusion of the aorta.21  Further opportunities for research and development exist for temporary haemorrhage control, including how these techniques can be deployed in the emergency department or at the incident scene.  

Exsanguinating patients need optimal blood product resuscitation alongside early intervention.  ADespite all centres having had major haemorrhage protocols which were not dependent on blood tests for release of products, but overall only 2% of all massive haemorrhage patients in our study received what might be considered optimal resuscitation - FFP:PRBC ratios of 1:2 or higher, and platelets and cryoprecipitate within the first hour of arrival.22  As with previous studies, there was a survival benefit in patients who received higher doses of plasma, even observed within the first 3 hours.23,24 Delivery of platelets and cryoprecipitate was delayed or even absent, an important finding especially in light of recent identification of severe fibrinogen loss in trauma-induced coagulopathy.25 New major haemorrhage protocols should assure early delivery of blood components to exsanguinating patients, and research is required into the delivery of higher dose or concentrated therapies in this critical time window.

A further finding of our study was the variation in blood product delivery that occurs during haemorrhage management, something identified by other international studies.24 As transfusion components have to be thawed, usually in a distant laboratory, there is an almost inevitable ‘boom and bust’ pattern of delivery where at times packs of multiple products are present and times when there is nothing and teams are waiting for products to arrive.  This often results in the inappropriate transfusion of crystalloids or administration of vasopressors to maintain circulation, to the ultimate detriment of the patient.  Some protocols manage this problem with the continuous delivery of products, but there are concerns with excessive waste with this strategy.  Alternatively clinicians need to predict on-going transfusion requirements using clinical criteria and/or point-of-care assessments to request products earlier in the transfusion cycle. There is a clear opportunity to improve practice and outcomes by improving the consistency of delivery of red cell and coagulation components during critical haemorrhage.

Although many patients succumbed quickly from severe haemorrhage, around 50% of deaths occurred after the first 24 hours.  Causes of late death in trauma include severe brain injury, multiple organ failure, pulmonary embolism and infection. The  However the actual mode of these late deaths was not collected as part of this study, and has not been characterised in detail, and but this clearly represents a further opportunity to improve outcomes in this cohort. Head injury was stated as a specific cause in (19%) 8/43 cases up to 24 hours. Furthermore patients who are discharged from hospital are considered to be ‘survivors’, but we have shown that a further 5% of deaths occur after discharge (an estimated 250 additional deaths per year nationally). This may contribute to the known reduced life expectancy of trauma patients.26 Causes of death in these patients are almost completely unknown and further research into the long-term mortality and functional consequences of trauma haemorrhage is required to identify opportunities for prevention of these late deaths.

There are limitations to this observational study. Data was not complete for all patients, including timings of transfusions, despite close liaison between blood banks and research staff supported transfusion data collection which helped to minimise missing data. The inclusion criteria included activation of major haemorrhage protocol, to define a severe group of trauma patients requiring significant transfusion support. We did not collect detailed information on all admissions requiring more than 4 units of red cell transfusions, as this would include patients with surgical complications requiring transfusion, and so our calculations of the prevalence of severe trauma requiring more than 4 units of red cell transfusions may be underestimated. Finally, this study was undertaken at an early stage in national trauma network reorganisation and the findings may change when repeated. 
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Table 1: Baseline characteristics of eligible patients from participating centres






Age (years)*	38 (26-54)	38 (24-51)









Time from incident (mins)*	72 (54-96) 	68 (53-100) 
Heart rate**	107 (31) 	110 (33) 
Systolic BP (mmHg)**	109 (35) 	99 (38) 
GCS **	14 (6-15) 	12 (4-15) 
		

Time from incident data was available for 177 patients with major haemorrhage and 67 patients with massive haemorrhage. Heart rate was available for 412 (major haemorrhage) and 130 (massive haemorrhage) patients, systolic BP for 391 (major haemorrhage) and 124 (massive haemorrhage) patients and GCS for 431 (major haemorrhage) and 143 (massive haemorrhage) patients.






Number receiving PRBC(%)	442 (100%)	146 (100%)
PRBC (units) within 24 hours	7 (5-11)	15 (12-20)
Time to first PRBC (mins)	41 (11-122)	24 (11-68)
Units of PRBC in 30 days	9 (6-15)	18 (13-26)
		
Number receiving FFP (%)	330 (75%)	134 (92%)
FFP units within 24 hours	4 (0-7)	8 (4-12)
FFP:PRBC	0.5 (0-0.8)	0.5 (0.4-0.7)
Time to first FFP (mins)	87 (42.5-229)	67.5 (30-131.5)
		
Number receiving Plt (%)	197 (45%)	118 (81%)
Plt dose (pools)	0 (0-1)	2 (1-3)
Plt:PRBC	0 (0-0.1)	0.1 (0.1-0.2)
Time to first Plt (mins)	146.0 (72.5-364.0)	120 (63-257)
		
Number receiving Cryo (%)	122 (28%)	76 (52%)
Cryo dose (pools)	0 (0-1)	1 (0-2)
Cryo:PRBC	0 (0-0.1)	0.1 (0-0.2)




In-hospital mortality	117 (27%)	56 (38%)
Patients intubated	167/210 (80%)	64/73 (88%)
Admissions to critical care	328/394 (83%)	103/126 (82%)
Ventilator days 	2 (1-5)	2 (1-6)
Critical care length of stay	65 (2-14)	6 (2-15)
24 hour mortality	79/442 (18%)	37/146 (25%)
30 day mortality	119/442 (27%)	57/146 (39%)
One-year mortality	127/383 (33%)	56/125 (45%)
		

Overall hospital mortality was available for 210 (major haemorrhage ) and 173 (massive haemorrhage) patients.  Ventilator days was available for 167 and 64 major haemorrhage and massive haemorrhage patients respectively.  Time to first unit was available for 397 (major haemorrhage) and 124 (massive haemorrhage) red cell transfused patients, and for 300 (major haemorrhage) and 120 (massive haemorrhage) FFP transfused patients.  One year outcome data was available for 383 patients with major haemorrhage and 125 patients with massive haemorrhage.










Status at 3 hours		
Number receiving PRBCs (%)	67 (17 %)	141 (36 %) 
Median number of PRBC units	10 (7 – 15)	6 (4 – 9)
Median ISS (IQR)	33 (24-45)	29 (19-43)
Median SBP (IQR) at admission	99 (79 – 120)	96 (76 – 126)
Dead (%)	12 (18%)	7 (5%)
		
Status at 24 hours		
Number receiving PRBCs (%)	92 (24%)	206 (53%)
Median number of PRBC units	10 (8 – 17)	7 (5 – 12)
Median ISS (IQR)	29 (19-44)	28 (17-43)
Median SBP (IQR) at admission	100 (78 – 122)	107 (84 – 132)
Dead (%)	26 (28%)	25 (12%)
		

The results shown are for patients who received at least one unit of plasma. Patients who died within the first hour of admission are excluded (see text) 








A	National incidence of major and massive haemorrhage in England and Wales, by age band
B	Deaths at under 3 hours, under 24 hours, in hospital, and at one year, for patients with major and massive haemorrhage 

Figure 2
Blood component usage and patient deaths for the 401 patients with complete component information
A	Distribution of use of red cells over 24 hours (x axis) for patients with major and massive haemorrhage
B	Ratio of mean FFP to mean RBC given each hour during the first 24 hours (x axis) after admission for the 327 who survived the first 24 hours
C	Percentage of patients achieving a cumulative FFP:PRBC ratio ≥1:2 by time (x axis), during the first 24 hours after admission, for the 327 patients who survived the first 24 hours
D	Patients who received either platelets, cryoprecipitate, or both products, by time (x axis) during the first 24 hours post-admission, for all 327 patients who survived the first 24 hours
E	Deaths per hour during the first 24 hours (x-axis) after admission
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